|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
ClinicalTrials.gov and the New Final Rule (42 CFR Part 11): What Strategic Decisions Do You Need to Consider?
Many trial operators are still scratching their heads. After reading and re-reading the 177 pages of 42 CFR Part 11, “Final Rule for Clinical Trials Registration and Results Information,” can you honestly say:
If the answer is “no” — or even “maybe” — you’re not alone. This new final rule is full of changes large and small.
FDAnews is addressing the confusion with a new training session featuring a leading light of the FDA regulatory bar, Scott Cunningham Esq., translating the knottiest provisions of the final regulation into simple English. Here’s what you’ll discover:
This training session gives you what you need to know — in just 90 minutes. Don’t risk sanctions for non-compliance. Get up to speed before the inspectors come around.
Scott Cunningham Esq. is a partner in Covington & Burling’s San Francisco-based Food and Drug Practice Group, representing pharma, biotech, regenerative medicine, and medical device firms. His expertise covers the gamut of FDA regulatory issues, including new product development/approval, clinical trials, IRBs, Hatch-Waxman exclusivities, advertising/promotion, false claims compliance, orphan drugs, pediatric exclusivity, cGMP/manufacturing, import/export, controlled substances and SEC disclosure.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing